Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
Status:
Completed
Trial end date:
2018-06-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when
used as an adjunctive treatment to energy-based therapy for participants with moderate to
severe persistent facial erythema associated with rosacea.